Home/ Supplements/ Vitamin K/ Vitamin K2 Advantage 2,200 mcg

Vitamin K2 Advantage 2,200 mcg

product on market Tablet or Pill Source Naturals Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 75% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

This formula combines calcium with vitamins K1 and K2 to support bone health and mineral metabolism. There is strong evidence that vitamin K2 helps direct calcium into the bone matrix and away from arterial walls. However, overall evidence coverage for this specific ingredient profile is limited.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Vitamin K2 Advantage 2,200 mcg
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
Other Combinations
Product Type
75%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calcium
64 mg (6% DV)
1820 mcg (2275% DV)
15.2× RDA — above typical dose 275 studies (A:9, B:175)
200 mcg (250% DV)
1.7× RDA — within safe limits 275 studies (A:9, B:175)
180 mcg (225% DV)
1.5× RDA — within safe limits 275 studies (A:9, B:175)

Other Ingredients

Microcrystalline Cellulose Dibasic Calcium Phosphate Hydroxypropylcellulose Magnesium Stearate Silica
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Suggested Use: 1 tablet daily with a meal.

Warnings & Precautions

Warning: If you are pregnant, may become pregnant, breastfeeding, or if you are taking anticoagulant drugs such as warfarin (Coumadin), consult your heath care professional before using this product.

Do not use if either tamper-evident seal is broken or missing.

Keep out of the reach of children.

Formulation Notes

Non GMO

Vitamin K2 Advantage uniquely delivers three powerful forms of vitamin K important to bone and heart health—K1, and two forms of K2, known as MK-4 and MK-7.

This complete vitamin K complex is vegan and non-GMO.

Additional Information

For bone and heart health

Non GMO validated

A potent form of K2, MK-7 works in two ways—it supports bone density and maintenance of normal vascular elasticity by helping direct proper amounts of calcium to the appropriate tissues. K2 MK-7 is highly bioavailable, lasts up to 12X longer than other forms of vitamin K, and is provided in this formula in a clinically backed dose.

Store in a cool, dry place.

SN2711 REV G167

Metadata

Product Details

UPC / SKU0 21078 02711 9
DSLD Entry Date2017-11-20
Product TypeOther Combinations
FormTablet or Pill
DSLD ID80669
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.